Effects of vitamin D supplementation on insulin sensitivity and androgen levels in vitamin-D-deficient polycystic ovary syndrome patients

2017 ◽  
Vol 44 (2) ◽  
pp. 270-277 ◽  
Author(s):  
Cihan Karadağ ◽  
Tevfik Yoldemir ◽  
Dilek Gogas Yavuz
Keyword(s):  
Vitamin D ◽  
Insulin Sensitivity ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Ovary Syndrome ◽  
Androgen Levels

scholarly journals EFFECT OF VITAMIN D SUPPLEMENTATION ON INSULIN SENSITIVITY AND ANDROGEN LEVEL IN VITAMIN D-DEFICIENT POLYCYSTIC OVARY SYNDROME PATIENTS

2018 ◽  
Vol 11 (12) ◽  
pp. 456
Author(s):  
Saba M Swadi Al-thuwaynee ◽  
Amaal Raad Ahmed
Keyword(s):  
Vitamin D ◽  
Insulin Sensitivity ◽  
Polycystic Ovary Syndrome ◽  
Testosterone Level ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Metabolic Parameter ◽  
Ovary Syndrome ◽  
Androgen Level ◽  
Low Level

Objectives: There is limited evidence that giving Vitamin D supplementation had a beneficial effect on insulin resistance and dysfunction of the menstrual cycle in females with polycystic ovary syndrome (PCOS). Thus, the aim of the present study is to evaluate the effect of Vitamin D supplementation on insulin sensitivity and androgen level in Iraqi females with PCOS.Methods: A randomized, blinded clinical trial design studied 60 Iraqi females with PCOS referring to the women’s counseling, outpatients at maternity and pediatrics teaching hospital in AL-Qadisiyah city, Iraq, and private clinic. Non-probabilistic sampling involved women aged from 18 to 45 years established on inclusion criteria. The patients’ basic data have been recorded. Then, we measured Vitamin D, testosterone level, and impaired glucose tolerance (IGT) test to all females. After the diagnosis of Vitamin D deficiency, Vitamin D was administering at 5000 units daily for 8 weeks. All data were remeasured after 2 months.Result: A total of 60 patients with polycystic syndrome enrolled in the study, age range from 18 to 39 years, mean age 27.48±5.95 years. The metabolic parameter have been checked at the beginning of the study, which include Vitamin D level 16.1±5.6, impaired glucose test reading 8.8±0.7 and testosterone level 4.5±0.64.. After 2 months of supplementation, there were 83.7% of patients reach the normal level of Vitamin D and 16.3% still had a low level of Vitamin D (p≤0.002) between two groups. In regard to IGT test after 2 months of supplementation, there were 51.6% of patients still who had impaired test while 48.4% reach the normal reading (p≤0.001).Conclusions: Women with PCOS have a statically significant low level of Vitamin D in mean, IGT test in the mean, and high level of testosterone, and there were inverse correlations between Vitamin D with IGT and testosterone.

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

scholarly journals Effects of vitamin D supplementation on serum lipid profile in women with polycystic ovary syndrome

Medicine ◽  
2020 ◽  
Vol 99 (23) ◽  
pp. e20621
Author(s):  
Xiao-yan Shi ◽  
Jia Yao ◽  
Si-min Fan ◽  
Pei-pei Hong ◽  
Yu-guo Xia ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Lipid Profile ◽  
Serum Lipid ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Serum Lipid Profile ◽  
Ovary Syndrome

scholarly journals Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome

2010 ◽  
Vol 56 (11) ◽  
pp. 1696-1700 ◽  
Author(s):  
Thozhukat Sathyapalan ◽  
John Shepherd ◽  
Charlotte Arnett ◽  
Anne-Marie Coady ◽  
Eric S Kilpatrick ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Statin Treatment ◽  
Vitamin D Supplementation ◽  
Significant Rise ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Markers Of Inflammation

BACKGROUND It has been shown that many women with polycystic ovary syndrome (PCOS) are 25-hydroxyvitamin D (25OHD) insufficient. Both statin treatment and vitamin D supplementation have been shown to improve biochemical hyperandrogenemia, insulin resistance, and markers of inflammation in patients with PCOS, raising the possibility that some of the statin effects are mediated through vitamin D. METHODS We conducted this randomized, double-blind placebo controlled study to assess the effect of atorvastatin on serum 25OHD concentrations in patients with PCOS. Forty medication-naive patients with PCOS were randomized to either atorvastatin 20 mg daily or placebo for 3 months. After completing the initial 3 months of atorvastatin or placebo, both groups of patients participated in a 3-month extension study with metformin 1500 mg daily. We measured changes in 25OHD concentrations by use of tandem mass spectrometry. RESULTS Mean (SD) baseline 25OHD concentrations were comparable between the 2 groups [45.9 (2.4) vs 44.8 (1.8) nmol/L; P = 0.7]. There was a significant increase in 25OHD concentrations with atorvastatin [45.9 (2.4) vs 60.8 (3.5) nmol/L] compared with placebo [44.8 (1.8) vs 41.8 (3.2) nmol/L; P = 0.02]. Three-month treatment with metformin maintained the improvement of 25OHD with atorvastatin compared to baseline [45.9 (2.4) vs 61.8 (3.5), P ≤ 0.01). There were no significant changes in 25OHD concentrations in the placebo group after 12 weeks of metformin. CONCLUSIONS Among patients with polycystic ovary syndrome, 12 weeks of atorvastatin led to a clinically significant rise in 25OHD concentrations. This may represent a beneficial pleiotropic effect of statins on 25OHD concentrations.

scholarly journals The Effect of Resistance Training in Water and Land with Vitamin D Supplementation on Anti-Mullerian Hormone in Women with Polycystic Ovary Syndrome

2019 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Seyed Ali Hosseini ◽  
Nasibeh Kazemi ◽  
Saeedeh Shadmehri ◽  
Shariat Jalili ◽  
Mozhgan Ahmadi
Keyword(s):  
Vitamin D ◽  
Resistance Training ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Ovary Syndrome

scholarly journals Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial

2019 ◽  
Vol 24 (1) ◽  
Author(s):  
Nearmeen M. Rashad ◽  
Azza H. Abd El-Fatah ◽  
Mohamed El-Bakry Lashin ◽  
Hala G. Abomandour ◽  
Reem M. Allam
Keyword(s):  
Vitamin D ◽  
Regression Analysis ◽  
Polycystic Ovary Syndrome ◽  
Clinical Features ◽  
Polycystic Ovary ◽  
Linear Regression Analysis ◽  
Vitamin D Supplementation ◽  
Metabolic Status ◽  
Ovary Syndrome ◽  
The Impact

Abstract Background Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of reproductive, endocrine, and metabolic functions. Vitamin D has an influence on metabolic and reproductive functions. This study was designed to explore the levels of free 25 hydroxycholecalciferol [25(OH)-D] in PCOS patients. We also aimed to clarify the impact of vitamin D supplementation on cardio-metabolic status, androgen profile, and clinical features of PCOS. Results Our results revealed significant lower levels of serum 25(OH)-D in PCOS women compared with healthy controls. Even more importantly, our results reported that 25(OH)-D levels were negatively correlated with cardio-metabolic risk factors, androgenic profile, and clinical features of PCOS. Stepwise multiple linear regression analysis revealed that carotid intima-media thickness (CIMT), fasting serum insulin (FSI), and fasting plasma glucose (FPG) were the main predictors of 25(OH)-D levels among other clinical and laboratory biomarkers. Considering the impact of VD supplementation in the PCOS group, there were significant improvements of cardio-metabolic risks, PCOS phenotype, and androgenic profile. Even more important, these results are associated with increasing 25(OH)-D serum levels after VD supplementations. Logistic regression analysis observed that androstenedione, FSI, and hirsutism score were independent predictors of response to VD supplementation. Conclusion The supplementation of VD for 12 weeks improved the cardio-metabolic and androgenic profiles of PCOS. Furthermore, VD supplementation could be a promising treatment of PCOS and its associated morbidity in PCOS-deficient women. Trial registration NCT04117750

Sign in / Sign up

Export Citation Format

Share Document